BACKGROUND: Limited data exist on the immunogenicity of the 2009 influenza A (H1N1) vaccine among immunocompromised persons, including those with human immunodeficiency virus (HIV) infection. METHODS: We compared the immunogenicity and tolerability of a single dose of the monovalent 2009 influenza A (H1N1) vaccine (strain A/California/7/2009H1N1) between HIV-infected and HIV-uninfected adults 18-50 years of age. The primary end point was an antibody titer of ≥ 1:40 at day 28 after vaccination in those with a prevaccination level of ≤ 1:10, as measured by hemagglutination-inhibition assay. Geometric mean titers, influenza-like illnesses, and tolerability were also evaluated. RESULTS: One hundred thirty-one participants were evaluated (65 HIV-infected and 66 HIV-uninfected patients), with a median age of 35 years (interquartile range, 27-42 years). HIV-infected persons had a median CD4 cell count of 581 cells/mm(3) (interquartile range, 476-814 cells/mm(3)) , and 82% were receiving antiretroviral medications. At baseline, 35 patients (27%) had antibody titers of >1:10. HIV-infected patients (29 [56%] of 52), compared with HIV-uninfected persons (35 [80%] of 44), were significantly less likely to develop an antibody response (odds ratio, .20; P = .003). Changes in the median geometric mean titer from baseline to day 28 were also significantly lower in HIV-infected patients than in HIV-uninfected persons (75 vs 153; P = .001). Five influenza-like illnesses occurred (2 cases in HIV-infected persons), but none was attributable to the 2009 influenza H1N1 virus. The vaccine was well tolerated in both groups. CONCLUSIONS: Despite high CD4 cell counts and receipt of antiretroviral medications, HIV-infected adults generated significantly poorer antibody responses, compared with HIV-uninfected persons. Future studies evaluating a 2-dose series or more-immunogenic influenza A (H1N1) vaccines among HIV-infected adults are needed (ClinicalTrials.gov NCT00996970).
BACKGROUND: Limited data exist on the immunogenicity of the 2009 influenza A (H1N1) vaccine among immunocompromised persons, including those with human immunodeficiency virus (HIV) infection. METHODS: We compared the immunogenicity and tolerability of a single dose of the monovalent 2009 influenza A (H1N1) vaccine (strain A/California/7/2009H1N1) between HIV-infected and HIV-uninfected adults 18-50 years of age. The primary end point was an antibody titer of ≥ 1:40 at day 28 after vaccination in those with a prevaccination level of ≤ 1:10, as measured by hemagglutination-inhibition assay. Geometric mean titers, influenza-like illnesses, and tolerability were also evaluated. RESULTS: One hundred thirty-one participants were evaluated (65 HIV-infected and 66 HIV-uninfectedpatients), with a median age of 35 years (interquartile range, 27-42 years). HIV-infectedpersons had a median CD4 cell count of 581 cells/mm(3) (interquartile range, 476-814 cells/mm(3)) , and 82% were receiving antiretroviral medications. At baseline, 35 patients (27%) had antibody titers of >1:10. HIV-infectedpatients (29 [56%] of 52), compared with HIV-uninfectedpersons (35 [80%] of 44), were significantly less likely to develop an antibody response (odds ratio, .20; P = .003). Changes in the median geometric mean titer from baseline to day 28 were also significantly lower in HIV-infectedpatients than in HIV-uninfectedpersons (75 vs 153; P = .001). Five influenza-like illnesses occurred (2 cases in HIV-infectedpersons), but none was attributable to the 2009 influenza H1N1 virus. The vaccine was well tolerated in both groups. CONCLUSIONS: Despite high CD4 cell counts and receipt of antiretroviral medications, HIV-infected adults generated significantly poorer antibody responses, compared with HIV-uninfectedpersons. Future studies evaluating a 2-dose series or more-immunogenic influenza A (H1N1) vaccines among HIV-infected adults are needed (ClinicalTrials.gov NCT00996970).
Authors: Terry Nolan; Jodie McVernon; Maryanne Skeljo; Peter Richmond; Ushma Wadia; Stephen Lambert; Michael Nissen; Helen Marshall; Robert Booy; Leon Heron; Gunter Hartel; Michael Lai; Russell Basser; Charmaine Gittleson; Michael Greenberg Journal: JAMA Date: 2009-12-21 Impact factor: 56.272
Authors: T Rowe; R A Abernathy; J Hu-Primmer; W W Thompson; X Lu; W Lim; K Fukuda; N J Cox; J M Katz Journal: J Clin Microbiol Date: 1999-04 Impact factor: 5.948
Authors: Sonia Molina-Pinelo; Alejandro Vallejo; Laura Díaz; Natalia Soriano-Sarabia; Sara Ferrando-Martínez; Salvador Resino; María Angeles Muñoz-Fernández; Manuel Leal Journal: J Antimicrob Chemother Date: 2009-07-16 Impact factor: 5.790
Authors: Hana M El Sahly; Charles Davis; Karen Kotloff; Jeffery Meier; Patricia L Winokur; Anna Wald; Christine Johnston; Sarah L George; Rebecca C Brady; Corinne Lehmann; Abbie Stokes-Riner; Wendy A Keitel Journal: J Infect Dis Date: 2012-01-24 Impact factor: 5.226
Authors: N F Crum-Cianflone; G Collins; G Defang; E Iverson; L E Eberly; C Duplessis; J Maguire; A Ganesan; B K Agan; T Lalani; T Whitman; C Brandt; D Faix; P J Blair; T Burgess Journal: Clin Exp Immunol Date: 2012-04 Impact factor: 4.330
Authors: George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim Journal: Pediatr Infect Dis J Date: 2013-11 Impact factor: 2.129
Authors: Robert F Pass; Sharon Nachman; Patricia M Flynn; Petronella Muresan; Terence Fenton; Coleen K Cunningham; William Borkowsky; James B McAuley; Stephen A Spector; Elizabeth Petzold; Wende Levy; George K Siberry; Ed Handelsman; L Jill Utech; Adriana Weinberg Journal: J Pediatric Infect Dis Soc Date: 2013-07-17 Impact factor: 3.164